These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 34242373)
1. Correction: Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children ˂5 years in Cameroon, 2011-2018. PLOS ONE Staff PLoS One; 2021; 16(7):e0254616. PubMed ID: 34242373 [TBL] [Abstract][Full Text] [Related]
2. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children. Ruiz-Contreras J; Picazo J; Casado-Flores J; Baquero-Artigao F; Hernández-Sampelayo T; Otheo E; Méndez C; Del Amo M; Balseiro C; Vaccine; 2017 Aug; 35(35 Pt B):4646-4651. PubMed ID: 28711388 [TBL] [Abstract][Full Text] [Related]
3. Correction: Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program. Richter L; Schmid D; Kanitz EE; Zwazl I; Pöllabauer E; Jasinska J; Burgmann H; Kundi M; Wiedermann U PLoS One; 2019; 14(2):e0212957. PubMed ID: 30789959 [TBL] [Abstract][Full Text] [Related]
4. Prediction of the potential benefit of different pneumococcal conjugate vaccines on invasive pneumococcal disease in German children. von Kries R; Hermann M; Hachmeister A; Siedler A; Schmitt HJ; Al-Lahham A; Reinert RR Pediatr Infect Dis J; 2002 Nov; 21(11):1017-23. PubMed ID: 12442022 [TBL] [Abstract][Full Text] [Related]
5. Correction: Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis. PLOS ONE Staff PLoS One; 2017; 12(11):e0189039. PubMed ID: 29190681 [TBL] [Abstract][Full Text] [Related]
6. Bacterial meningitis and pneumococcal serotype distribution in children in cameroon. Gervaix A; Taguebue J; Bescher BN; Corbeil J; Raymond F; Alcoba G; Kobela M; Tetanye E Pediatr Infect Dis J; 2012 Oct; 31(10):1084-7. PubMed ID: 22653488 [TBL] [Abstract][Full Text] [Related]
7. Characterization of pneumococcal meningitis before and after introduction of 13-valent pneumococcal conjugate vaccine in Niger, 2010-2018. Ousmane S; Kobayashi M; Seidou I; Issaka B; Sharpley S; Farrar JL; Whitney CG; Ouattara M Vaccine; 2020 May; 38(23):3922-3929. PubMed ID: 32327220 [TBL] [Abstract][Full Text] [Related]
8. Early impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis-Burkina Faso, 2014-2015. Kambiré D; Soeters HM; Ouédraogo-Traoré R; Medah I; Sangaré L; Yaméogo I; Sawadogo G; Ouédraogo AS; Ouangraoua S; McGee L; Srinivasan V; Aké F; Congo-Ouédraogo M; Ky Ba A; Whitney CG; Novak RT; Van Beneden C; J Infect; 2018 Mar; 76(3):270-279. PubMed ID: 29253559 [TBL] [Abstract][Full Text] [Related]
9. Correction: Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants. Wijmenga-Monsuur AJ; van Westen E; Knol MJ; Jongerius RM; Zancolli M; Goldblatt D; van Gageldonk PG; Tcherniaeva I; Berbers GA; Rots NY PLoS One; 2016; 11(5):e0155088. PubMed ID: 27168324 [TBL] [Abstract][Full Text] [Related]
10. Hospital-based Surveillance for Pediatric Bacterial Meningitis in the Era of the 13-Valent Pneumococcal Conjugate Vaccine in Ghana. Renner LA; Usuf E; Mohammed NI; Ansong D; Dankwah T; Kusah JT; Owusu SK; Awunyo M; Arhin B; Addo Y; Asamoah J; Biey JN; Ndow PS; Worwui A; Senghore M; Ntsama B; Mwenda JM; Diamenu SK; Adams BK; Antonio M Clin Infect Dis; 2019 Sep; 69(Suppl 2):S89-S96. PubMed ID: 31505622 [TBL] [Abstract][Full Text] [Related]
12. Impact of the 13-valent pneumococcal conjugate vaccine on the incidence of pneumococcal meningitis in children. Chapoutot AG; Dessein R; Guilluy O; Lagrée M; Wallet F; Varon E; Martinot A; Dubos F Epidemiol Infect; 2016 Feb; 144(3):607-11. PubMed ID: 26234410 [TBL] [Abstract][Full Text] [Related]
13. Nationwide Trends in Bacterial Meningitis before the Introduction of 13-Valent Pneumococcal Conjugate Vaccine-Burkina Faso, 2011-2013. Kambiré D; Soeters HM; Ouédraogo-Traoré R; Medah I; Sangare L; Yaméogo I; Sawadogo G; Ouédraogo AS; Hema-Ouangraoua S; McGee L; Srinivasan V; Aké F; Congo-Ouédraogo M; Sanou S; Ba AK; Novak RT; Van Beneden C; PLoS One; 2016; 11(11):e0166384. PubMed ID: 27832151 [TBL] [Abstract][Full Text] [Related]
14. Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada. Ricketson LJ; Conradi NG; Vanderkooi OG; Kellner JD Pediatr Infect Dis J; 2018 Jan; 37(1):22-27. PubMed ID: 28737622 [TBL] [Abstract][Full Text] [Related]
15. Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine. Hirose TE; Maluf EM; Rodrigues CO J Pediatr (Rio J); 2015; 91(2):130-5. PubMed ID: 25451210 [TBL] [Abstract][Full Text] [Related]
16. Clinical burden of pneumonia, meningitis and septicemia in Norway 2 years after 7-valent pneumococcal conjugate vaccine introduction. Munson S; Raluy-Callado M; Lambrelli D; Wasiak R; Eriksson D; Gray S Scand J Public Health; 2015 Aug; 43(6):657-66. PubMed ID: 25979727 [TBL] [Abstract][Full Text] [Related]
17. Pneumococcal meningitis before the introduction of 10-valent pneumococcal conjugate vaccine into the National Childhood Immunization Program in Poland. Polkowska A; Skoczyńska A; Paradowska-Stankiewicz I; Stefanoff P; Hryniewicz W; Kuch A; Lyytikäinen O; Nuorti JP Vaccine; 2019 Feb; 37(10):1365-1373. PubMed ID: 30638798 [TBL] [Abstract][Full Text] [Related]
18. The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014. Cohen R; Biscardi S; Levy C Hum Vaccin Immunother; 2016; 12(2):277-84. PubMed ID: 26905678 [TBL] [Abstract][Full Text] [Related]
19. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil. Brandileone MC; Almeida SCG; Minamisava R; Andrade AL Vaccine; 2018 May; 36(19):2559-2566. PubMed ID: 29650385 [TBL] [Abstract][Full Text] [Related]
20. Impact of 10- and 13-valent pneumococcal conjugate vaccines on incidence of invasive pneumococcal disease in children aged under 16 years in Germany, 2009 to 2012. Weiss S; Falkenhorst G; van der Linden M; Imohl M; von Kries R Euro Surveill; 2015 Mar; 20(10):21057. PubMed ID: 25788255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]